NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies

Figure 1

NRF2 activation causes cytoprotection from HER2-targeted agents, Pertuzumab and Trastuzumab. PE01 or SKOV3 cells in the presence of 1 nM HRG were either left untreated (H) or treated with 20 μg/mL of HER2 inhibitors Pertuzumab and Trastuzumab (H + I), 200 μM tBHQ (H + T), or combination of inhibitors and tBHQ (H + T + I). TBHQ was added 5 h in advance. Cell number was assessed indirectly by use of the MTT assay. Values shown are means ± S.D. of triplicates normalised to untreated controls expressed as 1. Statistical significance was calculated between H + I, H + T, and H + T + I groups by ONE WAY ANOVA followed by Tukey’s post hoc test according to the scale :  , :  , and :  .